ZZM-1220

Cat. No.: HY-156285

Molecular Formula: $C_{25}H_{29}N_5O_3$

Molecular Weight: 447.53

Target: Histone Methyltransferase; Apoptosis

Pathway: Epigenetics; Apoptosis

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (223.45 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.2345 mL	11.1724 mL	22.3449 mL
5 mM	0.4469 mL	2.2345 mL	4.4690 mL
10 mM	0.2234 mL	1.1172 mL	2.2345 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.5 mg/mL (5.59 mM); Clear solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (5.59 mM); Clear solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 2.5 mg/mL (5.59 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

ZZM-1220 is a histone lysine methyltransferase G9a/GLP covalent inhibitor with IC_{50}s of of 458 nM and 924 nM, respectively. ZZM-1220 inhibits H3K9me2 in cells and significantly induces apoptosis of triple-negative breast cancer (TNBC) cells and blocks the cell cycle in the G2/M phase[1].

IC_{50} & Target

G9a	GLP
458 nM (IC_{50})	924 nM (IC_{50})

REFERENCES

[1]. Qiangsheng Zhang, et al. Discovery of novel G9a/GLP covalent inhibitors for the treatment of triple-negative breast cancer. Eur J Med Chem. 2023 Sep 28:261:115841.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA